DIANA Biotechnologies

What DIANA Biotechnologies does

DIANA Biotechnologies, a.s. is a privately held Czech biotechnology company headquartered in Vestec near Prague, founded in 2017 by four scientists — Václav Navrátil (CEO/CTO and named inventor of the core DIANA technology), Martin Dienstbier (CFO/COO, ex-BCG), Jiří Schimer (Head of Chemistry), and Jan Tykvart (Head of Development). The company operates across four business segments built on its proprietary qPCR-based DIANA technology platform: Life Science reagents (PCR/RT-PCR mixes, polymerases, reverse transcriptases, RNase inhibitors), Monoclonal Antibody development (DIANA-Ab technology), Diagnostics (ultrasensitive PCR-based sepsis detection), and Drug Discovery Services (kinase inhibitor profiling across 230+ kinases). The platform was operationally validated through production of more than 6 million COVID-19 PCR tests during the pandemic, which covered approximately 40% of Czech testing capacity across 30+ clinical laboratories.

The product portfolio centers on differentiated reagent chemistries: SuperSens antibody-based hot-start technology delivering ~1-copy DNA/RNA detection; DBdirect technology enabling direct PCR/RT-PCR without nucleic acid extraction; the DB Ultima H RNase Inhibitor with oxidative resistance and stability above 55°C; DBscript Reverse Transcriptase with a 10-minute protocol; and DB AptaTaq DNA Polymerase with aptamer-based reversible inhibition. In 2025 the company executed a comprehensive refresh to the 2.0 series across PCR and RT-PCR mixes. Manufacturing runs from an ISO 13485-certified facility near Prague.

The business model combines one-time reagent sales (PCR/RT-PCR mixes, enzymes priced in EUR per pack size from 8 to 4,980 EUR) with professional services revenue (custom oligonucleotide synthesis, custom monoclonal antibody development, kinase inhibitor profiling) and a sepsis diagnostic product line. Distribution is executed through six regional distributors covering 18 European countries — BioTech (CZ/SK/HU), Caltag Medsystems (UK/IE), VitaSan (IT), Hoelzel Biotech (DACH), Techtum (Nordics), and Isogen Life Science (Benelux/Iberia) — supplemented by direct enterprise sales and a website e-commerce portal with an online quotation calculator for custom synthesis. Clinical validation of the sepsis diagnostic is being conducted at FN Motol and FN Olomouc hospitals under TACR TREND PROJECT FW10010005.

Name

DIANA Biotechnologies

Legal name

DIANA Biotechnologies, a.s.

Website

https://dianabiotech.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

DIANA Biotechnologies is a Czech biotech company that develops and manufactures proprietary qPCR-based molecular biology reagents, enzymes, RNase inhibitors, and sepsis diagnostics, serving life science researchers, clinical labs, and drug discovery clients across 18 European countries through a distributor-led model.

Ownership category

akta.pro rank

Product category

Molecular Biology Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• PCR reagent products
• RT-PCR diagnostic kits
• RNase inhibitors
• Monoclonal antibody development
• Sepsis PCR diagnostics

Headquarters

HQ city

Vestec

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Life Science Reagents: Sale of PCR mixes, RT-PCR mixes, enzymes, and RNase inhibitors to life science research laboratories and diagnostic companies. Products are sold in various pack sizes (100 rxns to 10,000 rxns) with pricing in EUR.
2. Custom Oligonucleotide Synthesis: Custom synthesis of oligonucleotides according to client specifications. Products are made to order based on buyer specifications with calculator-based pricing on the website.
3. Monoclonal Antibody Development: Custom monoclonal antibody development services using proprietary DIANA-Ab technology for unprecedented affinity and selectivity.
4. Kinase Inhibitor Profiling Services: Comprehensive kinase inhibitor profiling panels covering over 230 known kinases with competitive pricing for drug discovery clients.
5. Sepsis Diagnostics: Ultrasensitive PCR-based sepsis diagnostics solution providing results in less than 2 hours with ultra-sensitive detection of top 4 pathogens.

Pricing tiers

Go-to-market motion1 record

Distribution channels8 records

Marketing channels5 records

Core offering

DIANA Biotechnologies manufactures and sells molecular biology reagents (PCR and RT-PCR mixes, DNA polymerases, reverse transcriptases, and RNase inhibitors) under its proprietary DIANA, DBdirect, and SuperSens technology platforms, alongside a PCR-based sepsis diagnostic kit. It also provides fee-for-service offerings including custom oligonucleotide synthesis, kinase inhibitor profiling across 230+ kinases, and custom monoclonal antibody development using its DIANA-Ab technology.

Product overview

DIANA Biotechnologies is a diversified biotech company offering a comprehensive portfolio of molecular biology reagents and services. Their core product lines include: (1) PCR and RT-PCR Mixes 2.0 (DBdirect and standard variants with SuperSens technology) for direct or traditional PCR/RT-PCR workflows; (2) Enzymes including DBscript Reverse Transcriptase (fast 10-minute protocol), DB AptaTaq DNA Polymerase, and DB SuperSens Taq DNA Polymerase; (3) RNase Inhibitors (DB Ultima H as premium option, plus Bovine, Human, and Porcine variants) for RNA protection; (4) Ultrasensitive PCR-based sepsis diagnostics for detecting top 4 bacterial pathogens; (5) Services including custom oligonucleotide synthesis, kinase inhibitor profiling (230+ kinases), and monoclonal antibody development using proprietary DIANA-Ab technology. Their DBdirect technology enables direct PCR/RT-PCR without DNA/RNA extraction, while SuperSens technology provides exceptional sensitivity (detecting ~1 copy of DNA/RNA).

Differentiator

Problem solved

Functional benefit

Products and services

• DBdirect PCR Gel Mix SuperSens 2.0 (DB-1311) Next-generation direct PCR gel mix requiring no DNA extraction, featuring SuperSens technology for single-copy sensitivity, blue/yellow dyes for gel migration monitoring, and antibody hot-start. Sold to life science research and diagnostic laboratories.
• DBdirect PCR Gel Mix SuperSens 2.0 UDG (DB-1317) Direct PCR gel mix with SuperSens technology and UDG (uracil-DNA glycosylase) to prevent carryover contamination. No DNA extraction required, detects approximately 1 DNA copy. For life science and diagnostic laboratories.
• DBdirect PCR Probe Mix SuperSens 2.0 (DB-1308) Direct PCR probe mix for TaqMan probes with SuperSens technology; no DNA extraction needed, detects approximately 1 DNA copy, suitable for single-cell detection and multiplex reactions. Sold to research and diagnostic laboratories.
• DBdirect PCR Probe Mix SuperSens 2.0 UDG (DB-1309) Direct PCR probe mix with SuperSens technology and UDG for carryover contamination prevention, designed for TaqMan probes and detecting approximately 1 DNA copy. Stable for days at 25°C. For life science and diagnostic laboratories.
• DBdirect PCR SYBR Mix SuperSens 2.0 (DB-1310) Direct PCR SYBR mix with SuperSens technology for real-time DNA quantification; no DNA extraction needed, antibody hot-start, suitable for single-cell detection. Sold to research laboratories.
• DBdirect PCR SYBR Mix SuperSens 2.0 UDG (DB-1316) Direct PCR SYBR mix with SuperSens technology and UDG for carryover contamination prevention, using SYBR Green I for real-time DNA quantification, detecting approximately 1 DNA copy. For life science and diagnostic laboratories.
• DB RT-PCR Probe Mix SuperSens 2.0 (DB-1312) RT-PCR probe mix designed for TaqMan probes with SuperSens technology; detects approximately 1 RNA copy, stable for days at 25°C, suitable for single-cell detection and multiplex reactions. Sold to research and diagnostic laboratories.
• DB RT-PCR Probe Mix SuperSens 2.0 UDG (DB-1313) RT-PCR probe mix with SuperSens technology and UDG for carryover contamination prevention, designed for TaqMan probes with reverse transcriptase warm-start and approximately 1 RNA copy sensitivity. For life science and diagnostic laboratories.
• DB RT-PCR SYBR Mix SuperSens 2.0 (DB-1315) RT-PCR SYBR mix with SYBR Green I dye for real-time RNA quantification, SuperSens technology providing approximately 1 RNA copy sensitivity and robustness. Sold to research laboratories.
• DB RT-PCR SYBR Mix SuperSens 2.0 UDG (DB-1318) RT-PCR SYBR mix with SuperSens technology and UDG for carryover contamination prevention, SYBR Green I dye for real-time RNA quantification, approximately 1 RNA copy sensitivity. For life science and diagnostic laboratories.
• DBdirect RT-PCR Probe Mix SuperSens 2.0 (DB-1321) Direct RT-PCR probe mix for TaqMan probes; DBdirect technology enables direct detection without RNA extraction, SuperSens technology provides exceptional sensitivity and accuracy. Sold to research and diagnostic laboratories.
• DBdirect RT-PCR Probe Mix SuperSens 2.0 UDG (DB-1322) Direct RT-PCR probe mix with SuperSens technology and UDG; DBdirect technology eliminates RNA extraction, designed for TaqMan probes with reverse transcriptase warm-start. For life science and diagnostic laboratories.
• DBdirect RT-PCR SYBR Mix SuperSens 2.0 (DB-1323) Direct RT-PCR SYBR mix with SuperSens technology for real-time RNA quantification; DBdirect technology enables direct detection without RNA extraction, detecting approximately 1 RNA copy. Sold to research laboratories.
• DBdirect RT-PCR SYBR Mix SuperSens 2.0 UDG (DB-1324) Direct RT-PCR SYBR mix with SuperSens technology and UDG for carryover contamination prevention; DBdirect enables direct detection without RNA extraction, SYBR Green I dye for real-time quantification. For life science and diagnostic laboratories.
• DB Ultima H RNase Inhibitor (DB-1306) Highly engineered human-origin RNase inhibitor with full oxidative resistance and thermal stability above 55°C; the most potent inhibitor on the market for protecting RNA in direct RT-PCR, RNA-seq, and in vitro transcription applications. Sold to research and diagnostic laboratories.
• RNase Inhibitor Bovine (DB-1260) Bovine-origin RNase inhibitor with exceptional oxidation resistance and fewer cysteine residues for consistent performance; harmless for PCR enzymes and recombinant protein from E. coli. Sold to research laboratories.
• DBscript Reverse Transcriptase (DB-1276) MMLV mutant reverse transcriptase with reduced RNase H activity for improved yield and synthesis of longer cDNAs (>9 kb); features superfast 10-minute protocol, thermostability at 50-60°C, recombinant expression in E. coli. Sold to research and diagnostic laboratories.
• DBscript cDNA Synthesis Kit (DB-1285) Complete cDNA synthesis kit featuring DBscript Reverse Transcriptase and unique bovine RNase inhibitor; ultra-fast 10-minute protocol for two-step RT-PCR with reverse transcription at 50-60°C. Sold to research laboratories.
• DB AptaTaq DNA Polymerase (DB-1326) Gold standard Taq DNA polymerase with aptamer-based hot-start for ambient temperature preparation; half-life over 40 minutes at 95°C, amplification up to 5 kb, with 5'→3' polymerase and exonuclease activities for TaqMan probes. Sold to research and diagnostic laboratories.
• DB SuperSens Taq DNA Polymerase (DB-1328) High-thermostability Taq DNA polymerase with antibody-based hot-start for routine and demanding applications; half-life over 40 minutes at 95°C, suitable for high-throughput PCR, TA cloning, and DNA labeling. Sold to research and diagnostic laboratories.
• DB Lysis Buffer A (DB-1281) Genomic DNA extraction buffer for human cells, bacteria, yeast cells, and DNA viruses; used with PCR and RT-PCR mixes for single-cell detection. Sold to research laboratories.
• Ultrasensitive Sepsis Diagnostics PCR-based ultrasensitive sepsis diagnostics solution with results in less than 2 hours; proprietary qPCR-based DIANA technology provides unmatched sensitivity for detecting the top 4 sepsis pathogens (E. coli, S. aureus, K. pneumoniae, P. aeruginosa). For clinical diagnostic laboratories and hospitals.
• Custom Oligonucleotide Synthesis Custom synthesis of oligonucleotides according to client specifications, including various scales, purification options, and aliquot options; standard lead time of 30 working days, with most products shipped at ambient temperature. For research and diagnostic customers.
• Kinase Inhibitor Profiling Services Comprehensive kinase inhibitor profiling panels with coverage of 230+ known kinases at competitive pricing; customers can select panels suited to their drug discovery needs. For pharmaceutical and biotech drug discovery clients.
• Monoclonal Antibody Development Custom antibody development services using proprietary DIANA-Ab technology that enables development of mAbs with unprecedented affinity and selectivity, even against small molecules. For pharmaceutical and biotechnology companies.

Quantifiable outcome

• Sensitivity of 1 copy DNA/RNA detection with 2.0 series mixes
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and flagship.

• BioTech (ibiotech.cz)coreChannel Partner/ Reseller/ DistributorRegional distributor for Czechia, Slovakia and Hungary. BioTech handles distribution, ordering, and shipping of DIANA products in the region for easy customer access.
• Caltag MedsystemscoreChannel Partner/ Reseller/ DistributorRegional distributor for United Kingdom and Ireland. Handles local distribution and customer support for DIANA products in the UK and Irish markets.
• VitaSan LabscoreChannel Partner/ Reseller/ DistributorRegional distributor for Italy. Provides ordering and shipping services for DIANA products in the Italian market.
• Hoelzel BiotechcoreChannel Partner/ Reseller/ DistributorRegional distributor for Germany, Switzerland and Austria. Handles product distribution in the DACH region.
• Techtum LabscoreChannel Partner/ Reseller/ DistributorRegional distributor for Northern Europe covering Sweden, Norway, Finland, Denmark, and Iceland. Manages product distribution across Nordic countries.
• Isogen Life Science B.V.coreChannel Partner/ Reseller/ DistributorRegional distributor for Benelux, Spain and Portugal. Handles product distribution in Benelux and Iberian Peninsula markets.
• FN Motol HospitalflagshipStrategic or Co-development PartnerMajor Czech hospital collaborating on ultrasensitive sepsis diagnostics development. Part of TACR TREND PROJECT FW10010005. Hospital collects clinical samples and tests DIANA's qPCR-based sepsis diagnostic approach directly on site.
• FN Olomouc HospitalflagshipStrategic or Co-development PartnerMajor Czech hospital collaborating on ultrasensitive sepsis diagnostics development. Part of TACR TREND PROJECT FW10010005. Hospital collects clinical samples and validates DIANA's PCR-based sepsis solution in clinical settings.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Meridian Bioscience: US-based molecular diagnostics and life science reagents company focused on PCR-based test components and IVD kits for infectious disease. Comparable to DIANA in molecular diagnostics focus, especially in sepsis and infectious disease applications where both are developing PCR-based IVDs.
• TATAA Biocenter: Sweden-based provider of qPCR services, gene expression profiling, and molecular biology reagents with a European academic and clinical customer base. Direct overlap with DIANA's Life Science reagents and custom services portfolio, particularly in RT-PCR/qPCR products for gene expression research.
• GenScript: Global biotech offering custom monoclonal antibody development services, gene synthesis, and life science reagents. Direct overlap with DIANA's DIANA-Ab antibody development service line, particularly for high-affinity and challenging target antibody projects.
• Eurogentec: Belgium-based manufacturer of PCR/qPCR reagents, custom oligonucleotides, and recombinant proteins with a strong European distributor footprint. Direct overlap with DIANA's Life Science reagents business, particularly in custom oligo synthesis and PCR mix portfolios serving research and diagnostic markets.
• Solis BioDyne: Estonia-based molecular biology reagents manufacturer offering PCR mixes, qPCR enzymes, and reverse transcriptases with similar proprietary stabilization technology. Closely comparable to DIANA in product portfolio (PCR/RT-PCR mixes, enzymes, RNase inhibitors), European footprint, and SMB-to-mid-market distributor-led GTM model.

Broad incumbents

• Qiagen: Major molecular diagnostics and life science tools company with sample preparation technologies and PCR-based IVD products. DIANA's DBdirect (extraction-free PCR) technology competes with Qiagen's sample-prep-dependent workflows, and their IVD portfolio overlaps with DIANA's sepsis diagnostics ambitions.
• Bio-Rad Laboratories: Global life science and clinical diagnostics leader with a comprehensive PCR reagents portfolio (including SsoAdvanced mixes) and digital PCR systems. Competes with DIANA across both research-use reagents and IVD applications, with vastly larger resources and global reach.
• Roche Diagnostics: Global IVD leader with PCR-based clinical diagnostics, including sepsis and infectious disease panels. Represents the strategic ceiling for DIANA's sepsis diagnostics ambitions and the dominant player in European hospital IVD markets DIANA targets through its FN Motol and FN Olomouc partnerships.
• Thermo Fisher Scientific: Largest life science tools and IVD company globally, offering Applied Biosystems PCR reagents, TaqMan probe systems, and clinical diagnostics. Competes with DIANA in nearly every product category with substantially greater scale, distribution, and brand recognition.

Emerging players

• Jena Bioscience: Germany-based molecular biology and life science reagents company offering PCR reagents, enzymes, and custom synthesis services. Comparable in product portfolio breadth and European mid-market positioning, though smaller and more research-focused than DIANA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/DIANABiotechnologies
• LinkedInlinkedin.com/company/diana-biotechnologies
• Instagraminstagram.com/dianabiotech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DIANA Biotechnologies